Price
Financials
Consolidated, Rs crore| Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 7 | 7 | 9 | 3 | 5 | 2 | 3 | 3 | 2 | 1 | 2 |
| Expenses | 13 | 11 | 10 | 13 | 9 | 11 | 5 | -1 | 6 | 6 | 5 | 8 |
| Operating Profit | -4 | -4 | -3 | -4 | -6 | -6 | -3 | 3 | -3 | -3 | -3 | -6 |
| OPM % | -46% | -50% | -41% | -48% | -200% | -139% | -141% | 132% | -90% | -139% | -224% | -333% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52 |
| Interest | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 32 | 34 | 35 | 37 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 27 |
| Profit before tax | -34 | -35 | -35 | -37 | -40 | -42 | -39 | -33 | -41 | -43 | -44 | 19 |
| Tax % | -19% | -19% | -26% | -13% | -19% | -19% | -21% | -26% | -22% | -22% | -22% | -24% |
| Net Profit | -28 | -28 | -26 | -32 | -32 | -34 | -31 | -25 | -32 | -34 | -35 | 24 |
| EPS in Rs | -9.29 | -9.49 | -8.77 | -10.71 | -10.81 | -11.29 | -10.39 | -8.33 | -10.75 | -11.27 | -11.58 | 7.99 |
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 482 | 333 | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 8 |
| Expenses | 433 | 319 | 341 | 349 | 248 | 296 | 249 | 225 | 50 | 47 | 24 | 24 |
| Operating Profit | 50 | 14 | -14 | -75 | 14 | -36 | -19 | -1 | -18 | -15 | -12 | -15 |
| OPM % | 10% | 4.2% | -4.3% | -27% | 5% | -14% | -8% | -0.5% | -55% | -46% | -97% | -177% |
| Other Income | 1 | 0 | 0 | 107 | 1 | 2 | 3 | 2 | 1 | 0 | 0 | 52 |
| Interest | 29 | 48 | 56 | 60 | 70 | 70 | 86 | 98 | 96 | 110 | 125 | 106 |
| Depreciation | 13 | 14 | 23 | 19 | 31 | 23 | 25 | 24 | 69 | 17 | 17 | 40 |
| Profit before tax | 9 | -49 | -93 | -47 | -86 | -127 | -127 | -121 | -181 | -142 | -154 | -109 |
| Tax % | 46% | 10% | 16% | -3% | -22% | -8% | -8% | -8% | -18% | -20% | -21% | -30% |
| Net Profit | 5 | -53 | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 |
| EPS in Rs | 1.71 | -20.64 | -41.69 | -15.15 | -22.69 | -39.09 | -39.52 | -37.50 | -49.61 | -38.26 | -40.82 | -25.61 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -31% | -48% | -36% | -30% | ||
| Compounded Profit Growth | % | -2% | 4% | -6% | ||
| Stock Price CAGR | -20% | 0% | 0% | % | ||
| Return on Equity | % | % | % | % |
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 26 | 26 | 26 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Reserves | 300 | 311 | 203 | 157 | 82 | 278 | -47 | -166 | -477 | -591 | -713 | -854 |
| Borrowings | 332 | 395 | 501 | 539 | 581 | 670 | 772 | 767 | 638 | 636 | 636 | 107 |
| Other Liabilities | 97 | 118 | 105 | 98 | 92 | 88 | 159 | 260 | 349 | 478 | 615 | 1,201 |
| Total Liabilities | 755 | 850 | 835 | 825 | 785 | 1,066 | 914 | 890 | 541 | 552 | 568 | 484 |
| Fixed Assets | 406 | 500 | 610 | 571 | 542 | 892 | 739 | 716 | 356 | 339 | 322 | 205 |
| CWIP | 79 | 116 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 2 |
| Other Assets | 267 | 233 | 221 | 253 | 242 | 174 | 175 | 175 | 182 | 210 | 244 | 276 |
| Total Assets | 755 | 850 | 835 | 825 | 785 | 1,066 | 914 | 890 | 541 | 552 | 568 | 484 |
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 78 | 20 | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | -0 |
| Cash from Investing Activity | -113 | -147 | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | 65 |
| Cash from Financing Activity | 31 | 133 | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | -64 |
| Net Cash Flow | -5 | 5 | -3 | -2 | -5 | 1 | -0 | -0 | 0 | 0 | -0 | -0 |
| Free Cash Flow | -31 | -127 | -188 | -38 | -3 | -52 | 134 | 166 | 576 | 112 | 125 | 64 |
| CFO/OP | 164% | 143% | 1,193% | 77% | 12% | -162% | -692% | -14,269% | -2,700% | -765% | -1,065% | 3% |
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 101 | 88 | 161 | 194 | 130 | 99 | 6 | 0 | 0 | 0 | 0 |
| Inventory Days | 118 | 149 | 121 | 128 | 232 | 112 | 107 | 68 | 224 | 73 | 103 | 69 |
| Days Payable | 79 | 157 | 112 | 99 | 177 | 77 | 101 | 130 | 671 | 458 | 504 | 654 |
| Cash Conversion Cycle | 120 | 93 | 97 | 189 | 249 | 164 | 105 | -55 | -446 | -385 | -401 | -585 |
| Working Capital Days | -19 | -73 | 22 | 34 | 3 | -198 | -491 | -810 | -9,244 | -10,747 | -32,260 | -48,682 |
| ROCE % | 6% | -0% | -5% | -4% | -2% | -7% | -5% | -3% | -21% | -24% | -213% |
| Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.29% |
| DIIs | 0.01% | 0.01% | 0.03% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 26.71% | 26.71% | 26.69% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% |
| No. of Shareholders | 7,396 | 7,378 | 7,330 | 7,296 | 7,295 | 7,300 | 7,300 | 7,269 | 7,205 | 7,183 | 7,164 | 7,129 |
Fundamentals
Market Cap₹ 8.65 Cr.
Current Price₹ 2.90
Book Value₹ -276
ROCE%
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-30%
Compounded Profit Growth (TTM)-6%
Consolidated figures.
Valuation
Market capRs 9 Cr
Enterprise valueRs 116 Cr
Price to book-0.01x
Price to sales1.02x
EV / EBITDA3.11x
EV / sales13.65x
Earnings yield-882.77%
P/B, 3-year average-0.01x
P/B, 5-year average-0.10x
Profitability
Operating margin (excl. other income)-176.59%
Operating margin (incl. other income)438.47%
EBITDA margin438.99%
Pre-tax margin-1285.28%
Net profit margin-899.41%
Net margin, latest quarter1345.20%
ROE10.13%
ROA-14.51%
ROE, 3-year average17.44%
ROCE, 3-year average-119.56%
ROA, 3-year average-19.04%
ROE, 5-year average49.67%
ROCE, 5-year average-65.83%
ROA, 5-year average-18.04%
Tax rate30.02%
Other income / net worth-6.34%
Growth
Sales growth (latest year)-30.16%
Sales CAGR, 3 years-35.72%
Sales CAGR, 5 years-48.28%
Sales growth QoQ22.92%
Sales growth YoY (latest quarter)-31.13%
Per share
EPS (TTM)Rs -25.60
EPS (latest quarter)Rs 7.98
EPS, 3-year averageRs -39.54
EPS, 5-year averageRs -41.55
Book value per shareRs -276.26
Sales per shareRs 2.85
Cash flow per shareRs -0.16
Free cash flow per shareRs 21.46
Efficiency
Asset turnover0.02x
Fixed asset turnover0.04x
Inventory turnover5.31x
Inventory days69 days
Creditor days654 days
Cash conversion cycle-585 days
Working capital days-48682 days
Leverage
Total debtRs 107 Cr
Net debtRs 107 Cr
Debt to equity-0.13x
Net debt / EBITDA2.88x
Interest coverage-0.03x
Owners' fund to total sources-170.17%
Debt to assets22.14%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Investing Activity (latest year)Rs 65 Cr
Cash from Financing Activity (latest year)Rs -64 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs 64 Cr
FCFE (approx.: FCF + change in debt)Rs -464 Cr
Statement figures
Net sales (TTM)Rs 8 Cr
Net sales (latest year)Rs 8 Cr
Sales (latest quarter)Rs 2 Cr
Operating profit excl. other income (latest year)Rs -15 Cr
Operating profit (latest quarter)Rs -6 Cr
Other income (TTM)Rs 52 Cr
EBITDA (TTM)Rs 37 Cr
PBDT (TTM)Rs -69 Cr
Profit before tax (TTM)Rs -109 Cr
Tax (latest year)Rs -33 Cr
Net profit (TTM)Rs -76 Cr
Net profit (latest year)Rs -76 Cr
Net profit (latest quarter)Rs 24 Cr
Depreciation (TTM)Rs 40 Cr
Depreciation (latest quarter)Rs 27 Cr
Interest (TTM)Rs 106 Cr
Cost of goods sold (latest year)Rs 5 Cr
Total expenditure (latest year)Rs 24 Cr
Total income (latest year)Rs 61 Cr
Share capitalRs 30 Cr
ReservesRs -854 Cr
Shareholders' fundsRs -824 Cr
Total assetsRs 484 Cr
Net blockRs 205 Cr
InvestmentsRs 2 Cr
InventoryRs 1 Cr
Other liabilitiesRs 1,201 Cr
Shares outstanding (crore)2.98
Ownership
Promoter holding73.29% (+0.01 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | PDPL | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -12.1% | -2.8% | -9.3 pts |
| 1 month | -27.5% | -6.8% | -20.7 pts |
| 3 months | -31.8% | -7.6% | -24.1 pts |
| 6 months | +1.8% | +0.4% | +1.3 pts |
| 1 year | +9.4% | -9.9% | +19.4 pts |
| 2 years | -71.0% | -13.6% | -57.4 pts |
| 3 years | +11.5% | +14.2% | -2.6 pts |
| 5 years | -71.4% | +27.9% | -99.3 pts |
Red flags
F-score 4 of 8| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2022Sales ₹2 Cr -33.3% vs Mar 2021.
Net profit ₹24 Cr +196.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2022-02-23 | Extra Ordinary General Meeting | |
| 2021-09-15 | Annual General Meeting | |
| 2020-09-10 | Annual General Meeting | |
| 2019-08-22 | Annual General Meeting | |
| 2018-09-19 | Annual General Meeting | |
| 2017-09-21 | Annual General Meeting | |
| 2016-11-10 | Extraordinary General Meeting | |
| 2016-09-16 | Annual General Meeting | |
| 2015-08-21 | Annual General Meeting | |
| 2014-09-19 | Annual General Meeting | |
| 2013-09-25 | Annual General Meeting | |
| 2012-09-24 | Annual General Meeting | |
| 2011-09-23 | Annual General Meeting | |
| 2010-09-13 | Annual General Meeting/Dividend Rs.2/- Per Share/Bonus 1:3 | 0.7500 |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Parenteral Drugs (India) Ltd?
Parenteral Drugs (India) Ltd (PDPL) has a market capitalisation of Rs 8.65 Cr. at the 2023-08-21 close.
What were Parenteral Drugs (India) Ltd's latest quarterly results?
In the Mar 2022 quarter, Parenteral Drugs (India) Ltd sales was Rs 2 Cr (-33.3% vs Mar 2021) and net profit was Rs 24 Cr.